DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $69.10 +0.10 (0.14%) 6:16 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $69.10 +0.10 (0.14%) 6:16 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
DexCom (DXCM) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
DexCom's (DXCM) G7 Links With Tandem's Insulin Pump in Europe
by Zacks Equity Research
Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
DexCom (DXCM) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $125.45, moving +0.8% from the previous trading session.
Why DexCom (DXCM) Could Beat Earnings Estimates Again
by Zacks Equity Research
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw DexCom (DXCM) settling at $128.93, representing a +0.73% change from its previous close.
DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.
Here's Why DexCom (DXCM) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wearable Technology Market Gains Ground, 3 Stocks in Focus
by Moumi Mondal
In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.
DexCom (DXCM) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
DexCom (DXCM) closed at $123.98 in the latest trading session, marking a +1.76% move from the prior day.
Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes
by Zacks Equity Research
In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.
If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
by Zacks Equity Research
Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.
Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial
by Zacks Equity Research
Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.
DexCom (DXCM) Stock Moves -0.06%: What You Should Know
by Zacks Equity Research
The latest trading day saw DexCom (DXCM) settling at $124.09, representing a -0.06% change from its previous close.
Globus Medical (GMED) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.
Here's Why You Should Invest in Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.
Here's Why You Should Retain Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.
National Vision (EYE) Store Openings Aid, Macro Issues Stay
by Zacks Equity Research
In terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come.